Company intelligence / Profile preview

Ovie Therapeutics

New York, New York, United States of Americabusinesswire.com ↗

Ownership: Private
Employees: ~23
Development stage: Preclinical

Overview

OV329 is advancing in Phase 1 trials with topline data expected in Q3 2025. OV350 initiated first-in-human studies in Q1 2025. The company paused Phase 2 proof-of-concept study of OV888/GV101 in CCM.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Graviton Bioscience (for OV888/GV101)

Beyond the preview

Go deeper on Ovie Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovie Therapeutics.

Explore the full profile